zorevunersen
zorevunersen: developed by 2 companies · 2 clinical trials tracked.
zorevunersen evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
What is verified about zorevunersen, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| BIOGEN INC. (BIIB) | Phase 3 |
| Stoke Therapeutics, Inc. (STOK) | Phase 2 |
Clinical Trials (2)
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
Primary endpoint: Measurement of Seizure Change
An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001
Primary endpoint: Safety of multiple doses of zorevunersen
Frequently asked questions
Who is developing zorevunersen?
zorevunersen is being developed by BIOGEN INC., Stoke Therapeutics, Inc..
How many clinical trials involve zorevunersen?
BioSniper tracks 2 clinical trials involving zorevunersen.